S&P 500 extends rally to six straight weeks, posts new closing high for the year
https://seekingalpha.com/news/4044908-sp-500-extends-rally-to-six-straight-weeks-posts-new-closing-high-for-the-year?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news
Dec 08, 2023 - The S&P 500 (SP500) on Friday advanced 0.21% for the week to close at 4,604.37 points, posting losses in three out of five sessions
0
Adobe (ADBE) to Post Q4 Earnings: What's in the Offing?
https://www.zacks.com/stock/news/2195710/adobe-adbe-to-post-q4-earnings-what-s-in-the-offing?cid=CS-ZC-FT-analyst_blog|earnings_preview-2195710
Dec 08, 2023 - Adobe's (ADBE) fiscal Q4 performance is likely to reflect strength across the Digital Media and Digital Experience businesses.
0
Regeneron (REGN) Posts Positive Data on Blood Cancer Candidate
https://www.zacks.com/stock/news/2195671/regeneron-regn-posts-positive-data-on-blood-cancer-candidate?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2195671
Dec 08, 2023 - Regeneron's (REGN) multiple myeloma candidate demonstrates strong rates and depth of response in pre-treated patients.
0
Sanofi (SNY) Posts Upbeat Long-Term Outlook, Enhances R&D Focus
https://www.zacks.com/stock/news/2195113/sanofi-sny-posts-upbeat-long-term-outlook-enhances-r-d-focus?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2195113
Dec 07, 2023 - Sanofi (SNY) aims to generate annual sales of over 10 billion euros by 2030, driven by recently launched and potential new products. It intends to enhance R&D focus to become a market leader in immunology.
0
Nasdaq Showing Strong Move Back To The Upside, Dow Posting Modest Gain
https://www.rttnews.com/story.aspx?Id=3410250
Dec 07, 2023 - Stocks have moved mostly higher during trading on Thursday, rebounding following the downturn seen over the course of the previous session. The major averages have all moved to the upside, with the tech-heavy Nasdaq leading the advance. The strength on Wall Street may partly reflect ongoing optimism about the outlook for interest rates ahead of the release of the closely watched jobs report.
0
Old Dominion (ODFL) Posts LTL Unit Performance for November
https://www.zacks.com/stock/news/2194852/old-dominion-odfl-posts-ltl-unit-performance-for-november?cid=CS-ZC-FT-analyst_blog|company_news_-_corporate_actions-2194852
Dec 07, 2023 - Old Dominion's (ODFL) revenue per day fell nearly 1% year over year in November 2023 due to a 2.3% decrease in LTL tons per day.
0
Virco (VIRC) Gears Up to Post Q3 Earnings: What to Expect?
https://www.zacks.com/stock/news/2194431/virco-virc-gears-up-to-post-q3-earnings-what-to-expect?cid=CS-ZC-FT-analyst_blog|earnings_preview-2194431
Dec 06, 2023 - Virco's (VIRC) Q3 performance will likely reflect the impact of higher costs and seasonality.
0
Pfizer (PFE), Arvinas Post Upbeat Data From Breast Cancer Study
https://www.zacks.com/stock/news/2194285/pfizer-pfe-arvinas-post-upbeat-data-from-breast-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2194285
Dec 06, 2023 - Interim data from an early-stage study shows that treatment with Pfizer (PFE)/Arvinas' (ARVN) breast cancer combination therapy demonstrates encouraging clinical activity in heavily pre-treated patients.
0
Dollar General (DG) to Post Q3 Earnings: A Peek Into Comps
https://www.zacks.com/stock/news/2194017/dollar-general-dg-to-post-q3-earnings-a-peek-into-comps?cid=CS-ZC-FT-analyst_blog|earnings_preview-2194017
Dec 06, 2023 - Recognizing challenges in sales, specifically within discretionary spending, Dollar General (DG) is implementing strategic changes aimed at addressing these issues.
0
Olema posts Phase 1/2 data for lead asset in breast cancer
https://seekingalpha.com/news/4043544-olema-stock-falls-after-data-lead-asset-breast-cancer?source=feed_sector_healthcare
Dec 05, 2023 - Olema Pharmaceuticals (OLMA) announces interim results from a Phase 1b/2 clinical study for its breast cancer drug palazestrant. Read more here.
0